Parkinson's Disease
Conditions
Keywords
Continuous dopaminergic stimulation
Brief summary
SER-214 is a poly (2-ethyl-2oxazoline)(POZ) polymer conjugate of rotigotine, a potent dopamine agonist that has high affinity for the subclass of dopamine receptors in the brain that mediate dopamine signaling. SER-214 will be administered subcutaneously once a week via a standard 1 mL insulin syringe to determine the safety, tolerability and pharmacokinetic (PK) profile of released rotigotine and POZ-conjugate. Subjects in this study are eligible if they have early, stable or untreated Parkinson's disease and are still experiencing motor fluctuations.
Detailed description
Clinical evidence suggests that dopamine agonists should be considered as an initial or early symptomatic therapy for PD. Current information indicates that the early use of long-acting dopaminergic agonists may protect against the development of motor complications by stimulating dopamine receptors in a non-pulsatile manner and by delaying the introduction of levodopa. In pre-clinical primate studies, L-dopa (short-acting, pulsatile) and dopaminergic agonists (long-acting; non pulsatile) provide comparable clinical benefit but with agonists inducing significantly less dyskinesia. Chronic L-dopa treated animals develop gene changes that are associated with abnormal neuronal firing patterns and dyskinesias which are not seen with long-acting dopamine agonists. Based on pre-clinical and clinical study results, treatment of Parkinson's patients with long-acting levodopa or dopamine agonists should provide symptomatic benefit, and significantly delay the onset of motor complications. This can be accomplished with duodopa or continuous sc apomorphine but these treatments are associated with significant side effects. To date, no practical method of providing continuous drug delivery using a dopaminergic agent for therapy of patients with early PD to prevent the development of motor complications has been advanced through clinical trials. SER-214 is being developed as a weekly sc injection that provides prompt onset of dopaminergic stimulation. Continuous levels of released rotigotine within the therapeutic window for relief of motor fluctuations have been observed in MPTP-treated cynomolgus macaques. PK determinations in normal monkeys for up to 13 weeks of treatment show that weekly injections of SER-214 provide continuous drug delivery of released plasma rotigotine within a predictable therapeutic range.
Interventions
DRUGSER-214
SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
Sponsors
Serina Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Female or male subjects 40-80 years of age inclusive 2. A diagnosis of idiopathic Parkinson's disease (PD) consistent with UK brain bank criteria 3. De novo PD patients and those on a stable regimen of anti-Parkinson's drugs for at least 4weeks prior to screening including anticholingerics, amantadine, MAO-B inhibitors, COMT inhibitors or levodopa, but not dopamine agonists 4. Free of clinically significant motor complications as determined by the investigator 5. Ability to complete up to four weeks of dosing once per week with two weeks of terminal wash-out PK 6. Ability to return to the clinic for blood sampling, clinical and laboratory assessment on scheduled days, based upon cohort 7. Mini Mental State Exam (MMSE) \> 26 8. Women of child-bearing potential (WOCBP) must use a reliable method of contraception (e.g., oral contraceptive or long-term injectable or implantable hormonal contraceptive, double-barrier methods \[such as condom plus diaphragm, condom plus spermicidal foam, condom plus sponge\], or intra-uterine devices), and must have a negative serum pregnancy test at Screening and negative urine pregnancy test at baseline 9. Willing and able to comply with the study requirements including follow-up 10. Provide written informed consent 11. Cognitively intact sufficient to understand and provide informed consent 12. Approved by a central Eligibility Monitoring Committee (EMC) confirmed by EMC signature on the Enrollment Authorization Form (EAF)
Exclusion criteria
1. Subject has previously participated in this study. 2. Myocardial infarction within the past six months from screening 3. Ischemic stroke or transient ischemic event within the past two years from screening 4. Known sensitivity to dopamine agonists including nausea/vomiting, orthostatic hypotension, excessive sleep or impulse control disorder 5. Any major organ disease that substantially impairs life expectancy 6. History of cancer, other than basal cell carcinoma, within the past 10 years or subjects with any laboratory or physical exam or diagnostic procedure finding suggestive of current malignancy 7. Subjects who are known to be immunosuppressed or are receiving chronic treatment with immunosuppressive drugs 8. Subject with an atypical or secondary Parkinsonian (e.g., due to drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or degenerative disease) 9. Any clinically significant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator, makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study. 10. Subject has moderate renal impairment (creatine \> 2.5) 11. Subject has moderate (Child-Pugh categorization B, score 7-9) or severe (Child-Pugh categorization C, score 10-15) hepatic impairment. 12. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (CSSRS) at Screening 13. Subject has known hypersensitivity to rotigotine or to any components or excipients of the study drug 14. Subject has a history of psychosis or hallucinations within the previous 12 months 15. Subject has received an investigational drug within 30 days of screening or is currently participating in an investigational drug or investigational device trial 16. Subject, who, for any reason, is judged by the Investigator to be inappropriate for this study, including a subject who is unable to communicate or cooperate with the Investigator or who has/had a clinically significant illness or abnormal physical examination that may compromise safety of the subject during the trial or affect ability of the subject to adhere to study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety - Adverse Events and Serious Adverse Events | From initial sc dose of SER-214 up to six weeks of follow-up | Change from Screening in frequency of adverse events (AEs) and serious adverse events (SAEs) at the Final Safety Visit |
| Percentage of patients in each cohort who discontinued therapy due to any adverse events {Tolerability} | From initial sc dose of SER-214 up to six weeks of follow-up | Percentage of patients in each cohort who discontinued therapy due to any adverse events will be used as an assessment of tolerability |
| Safety - Vital Signs | From initial sc dose of SER-214 up to six weeks of follow-up | Change from Screening in assessment of vital signs (pulse, blood pressure) at each study visit and Final Safety Visit |
| Safety - Abnormal Laboratory Results | From initial sc dose of SER-214 up to six weeks of follow-up | Change from Screening in number of participants with laboratory test values of potential clinical importance |
| Safety - Treatment-Emergent Adverse Events | From initial sc dose of SER-214 up to six weeks of follow-up | Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to \[study drug\] will be assessed by the investigator (Yes/No). |
| Safety - ECG Changes | From initial sc dose of SER-214 up to six weeks of follow-up | Change from Screening in assessment of electrocardiogram (ECG) parameters at each injection visit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Epworth Sleepiness Scale (ESS) | From Screening up to six weeks of follow-up | The ESS will be determined at Screening, first Follow-up visit, Final Safety Visit and any unscheduled visit to determine if escalating doses of SER-214 are associated with increase in somnolence |
| Fluctuation index | On injection days plasma samples will be taken at time 0, 1, 2, 4 and 8 hours | On injection days plasma samples will be taken at time 0 (baseline), 1, 2, 4 and 8 hours post injection. PK samples will be used to determine (a) released plasma rotigotine and (b) total SER-214. PK data will be used to determine the Fluctuation Index |
| Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease (QUIP) | From screening up to six weeks of follow-up | The QUIP will be assessed at Screening and on the Final Safety Visit and any unscheduled visit to determine if there is any association between Impulsive-Compulsive behavior and SER-214 dose |
| Columbia Suicide Severity Rating Scale (C-SSRS) | From Screening up to six weeks of follow-up | The C-SSRS will be determined at Screening and Final Safety Visit and any unscheduled visit. C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of Yes on actual attempt), preparatory acts toward imminent suicidal behavior (3)(Yes on preparatory acts or behavior), suicidal ideation (4) (Yes on wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)(Yes on Has subject engaged in non-suicidal self-injurious behavior). |
| Maximum plasma concentration [C(max)] | On injection days plasma samples will be taken at time 0, 1, 2, 4 and 8 hours | PK samples will be used to determine (a) released plasma rotigotine and (b) total SER-214. PK data will be used to determine the C(max) |
| Time to maximum concentration [T(max)] | On injection days plasma samples will be taken at time 0, 1, 2, 4 and 8 hours | PK samples will be used to determine (a) released plasma rotigotine and (b) total SER-214. PK data will be used to determine the T(max) |
| Dose-adjusted area under the curve (AUC) | On injection days plasma samples will be taken at time 0, 1, 2, 4 and 8 hours | PK samples will be used to determine (a) released plasma rotigotine and (b) total SER-214. PK data will be used to determine the dose-adjusted AUC |
| Unified Parkinson's Disease Rating Scale | From Screening up to six weeks of follow-up | The UPDRS total (Parts I, II and III) will be determined at each study site visit and the Final Safety Visit |
| Unified Parkinson's Disease Rating Scale - Motor Part III Only | From Screening up to six weeks of follow-up | The Motor UPDRS (Part III) will be determined as a separate outcome measure at each injection day visit |
Countries
United States
Outcome results
None listed